Shenlian Biotech: Plans to acquire a 237 million yuan stake in Shizhiyuan and develop innovative drug business

2026-03-02 01:56:27

Abstract generation in progress

Shenlian Bio announces that the company plans to use 237 million yuan of its own funds and self-raised funds (including bank acquisition loans) to acquire a controlling stake in Yangzhou Shizhiyuan Biotechnology Co., Ltd., an associate company, through its wholly-owned subsidiary Shanghai Bontiancheng Biopharmaceutical Co., Ltd., via equity transfer and capital increase. After the transaction is completed, Shanghai Bontiancheng’s equity in Shizhiyuan will increase from 16.99% to 40.65%. Shanghai Shenyuan Qihang Investment will acquire an additional 10.35% equity in Shizhiyuan for 79.9564 million yuan. Shanghai Bontiancheng and Shanghai Shenyuan Qihang will together hold 51.00% of Shizhiyuan’s equity. The company can control the voting rights of 51% of Shizhiyuan’s equity, making Shizhiyuan a controlling subsidiary of the company and consolidating it into the company’s financial statements.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.